Acquisition - April 27, 2015
Karo Bio Acquires Tanomed
Recently Karo Bio acquired 100 percent of the drug research company Tanomed AB for 20 MSEK. This deal gives Karo Bio access to Tanomed’s nasal spray to relieve and prevent the progression of the common cold by reinforcing the body’s own defenses, according to Biotech Umeå. The patented technology is based on Swedish research in […]
Collaboration - April 27, 2015
Juno, AZ Testing Cancer Remedy
Juno Therapeutics and AstraZeneca are joining forces to test their respective cancer treatments, combining new therapies designed to use the body’s immune system to combat tumors. Under the deal, the pair plans to jointly fund a Phase I study combining one of Juno’s CAR-T therapies and pair it with a promising antibody developed by MedImmune, […]
Uncategorized - April 27, 2015
Study: Infections Can Affect IQ
A Danish study shows that infections can impair one’s cognitive ability as measured on an IQ scale. The largest of its kind to date, the study indicates a clear correlation between infection levels and impaired cognition. “Our research shows a correlation between hospitalization due to infection and impaired cognition corresponding to an IQ score of […]
Uncategorized - April 27, 2015
Long Term Benefits for First Aid
A new study at Denmark’s Aalborg University Hospital shows that the chance of a person returning to work after a heart attack increases by 40 percent if that person gets immediate first aid in comparison with those who don’t get any help until an ambulance arrives. “When a bystander gives heart massage and artificial respiration […]
Uncategorized - April 26, 2015
Melatonin Use Up for Children
A recent Norwegian survey showed that melatonin use among children between ages 4 and 17 has increased annually from 2004 to 2012, and that children as young as 4 take the medication for several years. Melatonin is used to help people fall asleep. But some studies have shown that the drug delays puberty in some […]
Collaboration - April 24, 2015
AZ, Amgen Switch to Psoriasis
Amgen and partner AstraZeneca are preparing to deliver U.S. and European applications for their plaque psoriasis drug brodalumab by midyear. The two companies halted tests for brodalumab as an asthma medication. Amgen outlined the news in its quarterly report, which also notes a 14 percent drop in R&D spending. “Based on the recommendation of an […]
